

Patient ID SA00119653	Patient Name TESTINGHERBN, JESSICA	Birth Date 1981-12-26	Gender F	Age 37
Order Number SA00119653	Client Order Number SA00119653	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 16 Apr 2019 00:00		

HER Breast Semi Quant IHC Manual

Case Number CR-19-284

Interpretation

MCR

Right T7 osteoblastic lesion, core needle biopsy, original accession: SA19-158, block: SA19-158-1B

SPECIAL PROCEDURE REPORT

Breast Biomarker(s) for:

Invasive or metastatic breast carcinoma

Result(s):

HER2 by Immunohistochemistry (IHC) Negative (Score 0)

METHOD AND SCORING

Fixation: Test results are only valid for non-decalcified paraffin embedded specimens fixed in 10% neutral buffered formalin within 1 hour of acquisition and fixed between 6 and 72 hours. Delay to fixation, under fixation or over fixation fall outside of ASCO/CAP guidelines and may affect these results.

Fixation conditions for this specimen were indicated as falling outside of ASCO/CAP guidelines.

HER2 Breast Cancer Manual Scoring Method: Testing is performed using FDA approved Ventana Pathway HER2 (4B5) rabbit monoclonal primary antibody and a proprietary detection system. Controls used have: no expression (HER2 score of 0), low expression (HER2 score of 1+) and high expression (HER2 score of 3+). All controls show appropriate reactivity. Scoring is performed according to ASCO/CAP guidelines as follows: Score of 3+ is defined as circumferential membrane staining that is complete, intense and in greater than 10% of the invasive tumor cells; Score of 2+ is defined as weak to moderate complete membrane staining observed and in greater than 10% of the invasive tumor cells; or circumferential membrane staining that is complete, intense and in less than or equal to 10% of the invasive tumor cells; Score of 1+ is defined as incomplete membrane staining that is faint or barely perceptible and in greater than 10% of the invasive tumor cells; or weak to moderate complete membrane staining observed and in less than 10% of the invasive tumor cells; Score of 0 is defined as no staining observed or membrane staining that is incomplete and is faint or barely perceptible and in less than or equal to 10% of the invasive tumor cells.

HER2 References: Wolff AC, Hammond ME, Hicks DG, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. [published online ahead of print May 30, 2018]. J Clin Oncol. doi: 10.1200/JCO.2018.77.8738.

Material Received

MCR

A. SA19-158: Right T7 osteoblastic lesion, core needle biopsy 1 stained slide, 3 unstained slides

Report electronically signed by

MCR

JESSICA PHILLIPS

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



Patient ID SA00119653	Patient Name TESTINGHERBN, JESSICA	Birth Date 1981-12-26	Gender F	Age 37
Order Number SA00119653	Client Order Number SA00119653	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 16 Apr 2019 00:00		

Fixed in 10% NB formalin w/in 1 hr

MCR

No

Fixed in 10% NB formalin 6-72 hrs

MCR

No

Tumor type

MCR

Metastatic breast carcinoma

Tumor classification

MCR

Metastatic breast carcinoma

Tissue was decalcified

MCR

Unknown

Received: 17 Apr 2019 10:27

Reported: 17 Apr 2019 10:56

HER Breast IHC Automated NO Reflex

Interpretation

MCR

HER Breast IHC Automated NO Reflex was cancelled on 04/17/2019 at 10:43; This test is being converted from automated analysis to manual analysis. The automated test will be canceled and the manual test will be signed out in a separate report.

Received: 17 Apr 2019 10:27

Reported: 17 Apr 2019 10:43

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292